BioAge Labs (BIOA) EBT Margin (2025 - 2026)
BioAge Labs (BIOA) reported EBT Margin of 801.12% for Q1 2026, up 9702.0% on a YoY basis from 8.17% in Q1 2025, and down 58.77% sequentially from 504.58% in Q4 2025.
BioAge Labs (BIOA) EBT Margin (2025 - 2026) Analysis & Trends
BioAge Labs (BIOA) has 2 years of EBT Margin data on file, last reported at 801.12% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 9702.0% year-over-year to 801.12%; the trailing twelve-month figure through Mar 2026 stood at 890.35% (up 890724.0% YoY), and the FY2025 full-year result was 1400.11%, changed N/A from the prior year.
- EBT Margin retreated to 801.12% in Q1 2026, from 504.58% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 504.58% in Q4 2025 to a low of 1390.12% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 10.97% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 33.51% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -41.57% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 40.73% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.05% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 30.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.35% |
| 10 | BioAge Labs | 930.32 Mn | 930.32 Mn | -10.37 Mn | -801.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -801.12% |
| Dec 31, 2025 | -504.58% |
| Sep 30, 2025 | -1,390.12% |
| Jun 30, 2025 | -1,059.58% |
| Mar 31, 2025 | -898.14% |